Anti-cancer combinations

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S492000, C514S451000, C514S453000, C514S454000, 55, C424S649000

Reexamination Certificate

active

07863320

ABSTRACT:
The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a platinum compound which has anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and carboplatin. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

REFERENCES:
patent: 3678077 (1972-07-01), Nakanishi et al.
patent: 4602034 (1986-07-01), Briet et al.
patent: 4704355 (1987-11-01), Bernstein et al.
patent: 5126129 (1992-06-01), Wiltrout et al.
patent: 5281620 (1994-01-01), Denny et al.
patent: 5464826 (1995-11-01), Grindey et al.
patent: 5620875 (1997-04-01), Hoffman et al.
patent: 5817684 (1998-10-01), Fleisch et al.
patent: 5863904 (1999-01-01), Nabel et al.
patent: 5910505 (1999-06-01), Fleisch et al.
patent: 6174873 (2001-01-01), Wrenn
patent: 6194454 (2001-02-01), Dow
patent: 6667337 (2003-12-01), Wilson
patent: 6806257 (2004-10-01), Lee et al.
patent: 2001/0041713 (2001-11-01), Waldstreicher et al.
patent: 2003/0003092 (2003-01-01), Krissansen et al.
patent: 2004/0087611 (2004-05-01), Baguley et al.
patent: 2004/0204480 (2004-10-01), Wilson et al.
patent: 2005/0131059 (2005-06-01), Wang et al.
patent: 2006/0009505 (2006-01-01), Baguley et al.
patent: 2007/0060637 (2007-03-01), Wilson et al.
patent: 2007/0082937 (2007-04-01), Baguley et al.
patent: 2008/0070847 (2008-03-01), Wilson et al.
patent: 2008/0070848 (2008-03-01), Wilson et al.
patent: 2008/0070849 (2008-03-01), Wilson et al.
patent: 2015265 (1970-10-01), None
patent: 19721211 (1998-11-01), None
patent: 0278176 (1988-08-01), None
patent: 0326149 (1989-08-01), None
patent: 0385467 (1990-09-01), None
patent: 0488718 (1992-06-01), None
patent: 0551200 (1993-07-01), None
patent: 0743064 (1996-11-01), None
patent: 0584001 (1997-05-01), None
patent: 0121285.1 (2001-09-01), None
patent: 0206839.3 (2002-05-01), None
patent: 0225508.1 (2002-11-01), None
patent: 0604114.9 (2006-03-01), None
patent: 0157387.7 (2006-08-01), None
patent: 0517386.9 (2006-08-01), None
patent: 09040690 (1997-02-01), None
patent: 2001247459 (2001-09-01), None
patent: 336259 (1999-06-01), None
patent: 506060 (2000-07-01), None
patent: 99121332 (2001-07-01), None
patent: 2195946 (2003-01-01), None
patent: WO 91/04014 (1991-04-01), None
patent: WO 94/23753 (1994-10-01), None
patent: WO 95/09621 (1995-04-01), None
patent: WO 96/32418 (1996-10-01), None
patent: WO 96/36347 (1996-11-01), None
patent: WO 97/04761 (1997-02-01), None
patent: WO 97/34482 (1997-09-01), None
patent: WO 98/25600 (1998-06-01), None
patent: WO 98/25615 (1998-06-01), None
patent: WO 98/25616 (1998-06-01), None
patent: WO 98/42332 (1998-10-01), None
patent: WO 98/42334 (1998-10-01), None
patent: WO 98/42335 (1998-10-01), None
patent: WO 98/42336 (1998-10-01), None
patent: WO 98/42337 (1998-10-01), None
patent: WO 98/42345 (1998-10-01), None
patent: WO 98/42346 (1998-10-01), None
patent: WO 98/42650 (1998-10-01), None
patent: WO 00/10600 (2000-03-01), None
patent: WO 00/15176 (2000-03-01), None
patent: WO 00/16798 (2000-03-01), None
patent: WO 0048591 (2000-08-01), None
patent: WO 00/76497AI (2000-12-01), None
patent: WO 01/34135 (2001-05-01), None
patent: WO 01/34137 (2001-05-01), None
patent: WO 01/34197 (2001-05-01), None
patent: WO 01/34198 (2001-05-01), None
patent: WO 02/09700 (2002-02-01), None
patent: WO 03/020259 (2003-03-01), None
patent: WO 03/080044 (2003-10-01), None
patent: WO 2004/039363 (2004-05-01), None
patent: WO 2005/027974 (2005-03-01), None
patent: WO 2007/023302 (2007-03-01), None
patent: WO 2007/023307 (2007-03-01), None
patent: WO 2009/053681 (2009-04-01), None
Siemann et al, Vascular Targeting agents enhance chemotherapeutic agent activities in solid tumor therapy, International Journal of Cancer; 99, 1-6 (2002).
Barefoot, Speciation of platinum compounds: a review of recent applications in studies of platinum anticancer drugs, Journal of Chromatography B, 751 (2001) 205-211.
Goodman &Gilman's, The Pharmacological Basis of Therapeutics, Ninth Edition, (1996), Calabresi et al., Section X, Chemotherapy of Neoplastic Diseases, pp. 1225-1229.
Siemann et al. (abstract only, Proceedings of the American Association for Cancer Research, 2000, vol. 41, p. 525.
Lassen et al (Annals of Oncology, 7, 1996 pp: 365-371).
U.S. Appl. No. 12/064,632, filed Aug. 28, 2006, Green, et al.
U.S. Appl. No. 12/064,633, filed Aug. 25, 2006, Green, et al.
Aitken, et al.; “Synthesis and Antitumour Activity of New Derivatives of Flavone-8-acetic Acid (FAA), Part 4: Variation of the Basic Structure”; Arch. Pharm. Pharm. Med. Chem. (2000), 333(6):181-188.
Atwell, et al.; “Potential Antitumor Agents. 60. Relationships between Structure and in Vivo Colon 38 Activity for 5-Substituted 9-Oxoxanthene-4-acetic Acids”; J. Med. Chem. (1990), 33:1375-1379.
Atwell, et al.; “Synthesis and anti-tumor activity of topologically-related analogues of flavoneacetic acid”; Anti-Cancer Drug Design (1989), 4(2):161-169.
Avastin. Http://www.centerwatch.com/patient/drugs/dru851.html, Jun. 29, 2004.
Baguley, et al.; “Immunomodulatory Actions of Xanthenone Anticancer Agents”; BioDrugs; (1997), 8(2):119-127.
Baguley, et al.; “Mechanisms of Tumor Blood Flow Inhibition by The Antitumour Drug DMXAA (5,6-dimethylxanthenone-4-acetic acid”; Proceedings of the 11th NCI EORTC AACR Symposium; Copyright © 2000 Stichting NCI-EORTC Symposium on new drugs in cancer therapy; publ. By the AACR; Published as a Supplement to Clinical Cancer Research, vol. 6, Nov. 2000.
Baguley, et al.; Poster Abstract 138, of abstracts book for the 16th EORTC-NCI-AACR 2004 meeting on “Molecular Targets and Cancer Therapeutics”; Geneva, Switzerland (Sep. 28 to Oct. 1, 2004).
Baguley, et al.; “Potential of DMXAA combination therapy for solid tumors”; Expert Rev. Anticancer Ther. (2002), 2(5):593-603.
Baguley, et al.; “Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5, 6-dimethylxanthenone-4-acetic acid”; Cancer Chemother. Pharmacol (1993), 33(1):77-81.
Baguley, et al.; “Evidence that the 5-hydroxytryptamine antagonist, cyproheptadine, modulates nitric oxide production in mice in response to flavone acetic acid, vinblastine and other agents”; Biol. Nitric Oxide, Proc. Int. Meet.; Meeting Date 1991, vol. 2, (1992); 222-224.
Baguley, et al.; “Increased Plasma Serotonin Following Treatment With Flavone-8-Acetic Acid, 5,6-Dimethylxanthenone-4-Acetic Acid, Vinblastine, and Colchicine: Relation to Vascular Effects”; Oncology Research; (1997) 9(2), 55-60.
Begley, et al.; “The Blood-Brain-Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System”; J. Pharm. Pharmacol. (1996), 48:136-146.
Bibby, et al.; “Flavone acetic acid—from laboratory to clinic and back”; Anti-Cancer Drugs (1993), 4:3-17.
Bibby, et al.; “Reduction of Tumor Blood Flow by Flavone Acetic Acid: A Possible Component of Therapy”; J. Natl. Cancer Inst. (1989), 81:216-220.
Brem, et al.; “Interstitial chemotherapy with drug polymer implants for the treatment of recurring gliomas”; J. Neurosurg. (1991), 74:441-446.
Browne, et al.; “Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5, 6-dimethylxanthenone-4-acetic acid”; Anticancer Res. (1998), 18(6A):4409-4414.
Cao, et al.; “Interferon-inducible Protein 10 Induction and Inhibition of Angiogenesis in Vivo by the Antitumor Agent 5, 6-Dimethylxanthenone-4-acetic Acid (DMXAA)”; Cancer Research (2001), 61(4):1517-1521.
Cao, et al.; “Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tu

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Anti-cancer combinations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-cancer combinations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cancer combinations will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2682420

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.